References

REFERENCES

1. National Center for Health Statistics. SEER cancer statistics review, 1973-1995. Bethesda, MD: US National Cancer Institute, 1998.

2. Parkin DM, Muir C, Whelan SL, et al. Cancer incidence in five continents, vol VI. Lyon, France: International Agency for Research on Cancer Scientific Publications, 1992.

3. Seow A, Duffy S, McGee M, et al. Breast cancer in Singapore: trends in incidence 1968-1992. Int J Epidemiol 1996;25:40-45.

4. Nagata C, Kawakami N, Shimizu H. Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat 1997;44:75-82.

5. Hoover R. Breast cancer: geographic, migrant, and time-trend patterns. In: Fortner JSP, ed. Accomplishments in cancer research. New York: Lippincott-Raven, 1996.

6. Pike MC, Spicer DV, Dalimoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1991;15:48-65.

7. Tominaga S, Aoki K, Fujimoto I, Kurihara M. Cancer mortality and morbidity statistics: Japan and the world - 1994. Tokyo: Japan Scientific Societies Press, 1994.

8. Heck KE, Pamuk ER. Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol 1997;145:366-372.

9. Krieger N. Social class and the black/white crossover in the age-specific incidence of breast cancer: a study linking census-derived data to population-based registry records. Am J Epidemiol 1990;131:804-814.

10. Rosner B, Colditz G. Nurses' health study: log-incidence mathematic model of breast cancer incidence. J Natl Cancer Inst 1996;88:359-364.

11. Stanford J, Herrinton L, Schwartz S, Weiss N. Breast cancer incidence in Asian migrants to the United States and their descendants. Epidemiology 1995;6:1819-1827.

12. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85: 1819-1827.

13. Kolonel L. Cancer patterns of four ethnic groups in Hawaii. J Natl Cancer Inst 1980;65:1127-1139.

14. Dunn J. Cancer epidemiology in populations of the United States - with emphasis on Hawaii and California - and Japan. Cancer Res 1975;35:3240-3245.

15. Yu H, Harris R, Gao Y, Gao R, Wynder E. Comparative epidemiology of cancers of the colon, rectum, prostate, and breast in Shanghai: China versus the United States. Int J Epidemiol 1991;20:76-81.

16. Shimizu H, Ross RK, Bernstein L, Yatani R. Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966.

17. Tominaga S. Cancer incidence in Japanese in Japan, Hawaii, and western United States. Natl Cancer Inst Monogr 1985;69:83-92.

18. Kliewer E, Smith K. Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst 1995;97:1154 - 1161.

19. Young C. Changes in demographic behaviour of migrants in Australia and the transition between generations. Population Studies 1991;45: 67 - 89.

20. Bouchardy C. Cancer in Italian migrant populations: France. IARC Sci Publ 1993;123:149-159.

21. Robbins A, Brescianini S, Kelsey J. Regional differences in known risk factors and the higher incidence of breast cancer in San Francisisco. J Natl Cancer Inst 1997;89:960-965.

22. Sturgeon S, Schairer C, Gail M, McAdams M, Brinton L, Hoover R. Geographic variation in mortality from breast cancer among white women in the United States. J Natl Cancer Inst 1995;87:1846-1853.

23. Centers for Disease Control and Prevention. Breast cancer on Long Island, New York. Washington: U.S. Department of Health and Human Services, 1992.

24. White E, Lee C, Kristal A. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst 1990;82:1546-1552.

25. Liff J, Sung J, Chow W, Greenberg R, Flanders W. Does increased detection account for the rising incidence of breast cancer? Am J Public Health 1991;81:462-465.

26. Lantz P, Remington P, Newcomb P. Mammography screening and increased incidence of breast cancer in Wisconsin. J Natl Cancer Inst 1991;83:1540-1546.

27. Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: relevance of early detection. Cancer Causes Control 1991;2:67-74.

28. Feuer E, Wun M. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization: a dynamic population model approach. Am J Epidemiol 1992;136:1423-1436.

29. Miller BA, Feuer EJ, Hankey BF. Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 1993;43:27-41.

30. Chu K, Tarone R, Kessler L. Recent trends in breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-1579.

31. Chevarley F, White E. Recent trends in breast cancer mortality among white and black US women. Am J Public Health 1997;87:775-781.

32. Persson L, Bergstrom R, Barlow L, Adami H-O. Recent trends in breast cancer incidence in Sweden. Br J Cancer 1998;77:167-169.

33. Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ 1995;311:1391-1395.

34. Matheson I, Tretli S. Changes in breast cancer incidence among Norwegian women under 50. Lancet 1996;348:900-901.

35. Jin F, Shu X-O, Devesa S, Zheng W, Blot W, Gao Y-T. Incidence trends for cancers of the breast, ovary, and corpus uteri in urban Shanghai, 1972-1989. Cancer Causes Control 1993;4:355-360.

36. Hermon C, Beral V. Breast cancer mortality rates are levelling off or beginning to decline in many western countries: analysis of time trends, age-cohort and age-period models of breast cancer mortality in 20 countries. Br J Cancer 1996;73:955-960.

37. Beral V, Hermon C, Reeves G, Peto R. Sudden fall in breast cancer death rates in England and Wales. Lancet 1995;345:1642-1611.

38. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:233-243.

39. MacMahon B, Trichopoulos D, Brown J. Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 1982;30:427-431.

40. Bernstein L, Ross R. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48-62.

41. Garland M, Hunter DJ, Colditz GA, et al. Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of women. Am J Epidemiol 1998;147: 636-643.

42. Bruzzi P, Negri E, La Vecchia C. Short term increase in risk of breast cancer after full term pregnancy. BMJ 1988;47:757-762.

43. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. "Hormonal" risk factors, "breast tissue age," and the age-incidence of breast cancer. Nature 1983;303:767-770.

44. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994;139:819-835.

45. Rosner B, Colditz G. Extended mathematical model of breast cancer incidence in the Nurses' Health Study. J Natl Cancer Inst 1996;88: 359-364.

46. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia A, Adami H-O. Transient increase in risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.

47. Russo J, Tay LK, Russo IK. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.

48. La Vecchia C, Negri E, Boyle P. Reproductive factors and breast cancer: an overview. Soz Praventivmed 1989;34:101-107.

49. Trichopoulos D, Hsieh C, MacMahon B, Lin T, Lowe C, Mirra A. Age at any birth and breast cancer risk. Int J Cancer 1983;31: 701-704.

50. Lane-Claypon JE. A further report on cancer of the breast, with special reference to its associated antecedent conditions. London: Ministry of Health, 1926.

51. Russo J, Russo IH. The etiopathogenesis of breast cancer prevention. Cancer Lett 1995;90:81-89.

52. Romieu I, Hemandez-Avila M, Lazcano E, Lopez L, Romero-Jaime R. Breast cancer and lactation history in Mexican women. Am J Epidemiol 1996;132:17-26.


53. Committee on Nutrition, American Academy of Pediatrics. Pediatric nutrition handbook, 3rd ed. LA Baness, ed. Elk Grove Village, IL: American Academy of Pediatrics, 1993.


54. Gordon A, Nelson L. Characteristics and outcomes of WIC participants and non-participants: analysis of the 1988 National Maternal and Infant Health Survey. Alexandria, VA: US Department of Agriculture, 1995.


55. Ventura S, Taffel S, Mosher W, Wilson J, Hensiiax AS. Trends in pregnancies and pregnancy rates: estimates for the United States, 1980-92. Monthly vital statistics report 43[Suppl]:11. Hyattsville, MD: National Center for Health Statistics; 1995.


56. Kline J, Stein Z, Susser M. Conception to birth: epidemiology of prenatal development. New York: Oxford University Press, 1989.


57. Krieger N. Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development, and social gradients, including black/white differences in breast cancer incidence. Breast Cancer Res Treat 1989;13:205-223.


58. Brind J, Chinchilli V, Severs W, Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J Epidemiol Community Health 1996;50: 481-496.


59. Palmer J, Rosenberg L, Rao R. Induced and spontaneous abortion in relation to risk of breast cancer (United States). Cancer Causes Control 1997;8:841-849.


60. Newcomb P, Storer B, Longnecker M, Mittendorf R, Greenberg E, Willett W. Pregnancy termination in relation to risk of breast cancer. JAMA 1996;275:283-287.


61. Melbye M, Wohlfahrt J, Olsen J. Induced abortion and the risk of breast cancer. N Engl J Med 1997;336:81-85.


62. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-6l3.


63. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927-934.


64. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer - from 54 epidemiological studies. Lancet 1996;47:1713-1727.


65. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987;126:319-325.


66. Moolgavkar S. Cancer models. Epidemiology 1990;1:419-420.


67. Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 1954;8:1-12.


68. Moolgavkar S, Knudson A, Jr. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981;66:1037-1052.


69. Hsieh C, Pavia M, Lambe M. Dual effect of parity on breast cancer risk. Eur J Cancer 1994;30A:969-973.


70. Janerich DT, Hoff MB. Evidence for a crossover in breast cancer risk factors. Am J Epidemiol 1982;116:737-742.


71. Gray GE, Henderson BE, Pike MC. Changing ratio of breast cancer incidence rates with age of black females compared with white females in the United States. J Natl Cancer Inst 1980;64:461-463.


72. U.S. Department of Commerce, Bureau of the Census. Fertility of American women: June 1983. Current Population Report. Series P-20, population characteristics, no 395. Washington: U.S. Bureau of the Census; 1983.


73. Bank W. Social indicators of development 1993. Baltimore: The Johns Hopkins University Press; 1991.


74. Chen J, Campbell TC, Junyao L, Peto R. Diet, life-style, and mortality in China: a study of the characteristics of 65 Chinese counties. Oxford: Oxford University Press, 1990.


75. Colditz GA. A blomathematical model of breast cancer incidence: the contribution of reproductive factors to variation in breast cancer incidence. In: Fortner JG, Sharp PA, eds. Accomplishments in cancer research 1996. Philadelphia: Lippincott-Raven, 1997: 116-121.


76. Harris JR, Lippman ME, Veronesi U, Willett WC. Breast cancer. N Engl J Med 1992;327:319-328.


77. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-141


78. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998;90:1371-1388.


79. Hankinson SE, Manson JE, London SJ, Willett WC, Speizer FE. Laboratory reproducibility of endogenous hormone levels in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1994;3: 51-56.


80. Potischman N, Falk RT, Liaming VA, Siiteri PK, Hoover RN. Reproducibility of laboratory assays for steroid hormones and sex-hormone binding globulin. Cancer Res 1994;54:5363-5367.

81. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299.


82. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-197.


83. Toniolo P, Koenig KL, Pasternack BS, et al. Reliability of measurements of total, protein-bound, and unbound estradiol in serum and plasma. Cancer Epidemiol Biomarkers Prev 1994;3:47-50.


84. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3 year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-654.


85. Micheli A, Muti P, Pisani P, et al. Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. J Clin Epidemiol 1991;44:1055-1061.


86. Muti P, Trevisan M, Micheli A, et al. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 1996;5:917-922.


87. Roberts KD, Rochefort JG, Bleau G, Chapdelaine A. Plasma oestrone sulphate concentrations in postmenopausal women. Steroids 1980;35: 179-186.


88. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endrocrinol Metab 1996:1460-1464.


89. Thomas HV, Reeves GK, Key TJA. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-928.


90. Moore JW, Clark GM, Bulbrook RD, et al. Serum concentrations of total and nonprotein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer 1982;29:17-21.


91. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.


92. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;75:1075-1079.


93. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125:791-799.


94. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;136:203-232.


95. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-509.


96. Fishman J, Schneider J, Hershcopf RJ, Bradlow HL. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer: a case-control study. J Steroid Biochem 1984;20:1077-1081.


97. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-3051.


98. Zheng W, Dunning L, Jin F, Holtzman J. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1998:7:85-86.


99. Adlercreutz H, Fotsis T, Hockerstedt K, et al. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 1989;34:527-530.


100. Gordon GB, Shantz LM, Talalay P. Modulation of growth differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 1987;26:355-382.


101. Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-1481.


102. Seymour-Munn K, Adams J. Estrogenic effects of 5-androstene-3beta, 17beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 1983,112: 486-491.


103. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JMG, Koenig KL, Shore RE, Kim MY. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145:1030-1038.


104. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533-539.


105. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996:98:291-296.


106. Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 1990;50:3859-3862.


107. Dorgan JF, Stanczyk FZ, Longcope C, et al. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfite, and 5-androstene-3-beta, 17-beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1997;6:177-181.


108. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992;52:1-4.


109. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev 1979;1:74-109.


110. Partridge RK, Hahnel R. Prolactin receptors in human breast carcinoma. Cancer 1979;43:643-646.


111. Malarkey WB, Kennedy M, Allred LE, Lo G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 1983;56:673-677.


112. Beedy DI, Easty GC, Gazet JC, Grigor K, Neville AM. An assessment of the effects of hormones on short term organ cultures of human breast carcinoma. Br J Cancer 1975; 31:317-328.


113. Herman V, Kalk WJ, de Moor NG, Levin J. Serum prolactin after chest wall surgery: elevated levels after mastectomy. J Clin Endocrinol Metab 1981;52:148-151.


114. Yen SSC, Jaffe RB. Reproductive endocrinology. Philadelphia: WB Saunders, 1991.


115. Wang DY, De Stavola BL, Bulbrook RD, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992;21:214-221.


116. Hankinson SE, Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-634.


117. Zapf J, Froesch ER. Insulin-like growth factors; somatomedins: structure, secretion, biological actions and physiological role. Horm Res 1986;24:121-130.


118. Yang XF, Beamer W, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 1996;56:1509-1511.


119. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-1697.


120. Ruan W, Newman C, Kleinberg D. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci U S A 1992;89: 10872-10876.


121. Tomell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson OGP. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. JSteroid Biochem Mol Biol 1992;43:237-242.


122. Ng S, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature (Medicine) 1997;3:1141-1144.


123. Michels KB, Trichopoulos D, Robins JM, et al. Birthweight as a risk factor for breast cancer. Lancet 1996;348:1542-1546.


124. Hunter DJ, Willett WC. Diet, body size, and breast cancer. Epidemiol Rev 1993;15:110-132.


125. Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus: relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991;29:219-225.


126. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-752.


127. Bruning PF, Van Doom J, Bonfrer JMG. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 1995;62:266-270.


128. Peyrat JP, Bonneterre J, Hecquet B, Hondermarck H, Adenis A. Plasma IGF-I concentrations in human breast cancer. Eur J Cancer 1993;29a:492-497.


129. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.


130. Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995:36:1296-1302.


131. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet 1990;335:939-940.


132. Ekbom A, Hsieh CC, Lipworth L, Adami HQ. Trichopoulos D. Intrauterine environment and breast cancer risk in women: a population-based study. J Natl Cancer Inst 1997;89:71-76.


133. Institute of Medicine, Committee on the Relationship Between Oral Contraceptives and Breast Cancer. Oral contraceptives and breast cancer. Washington: National Academy Press; 1991.


134. Annegers JF. Patterns of oral contraceptive use in the United States. Br J Rheumatol 1989;28 [Suppl 1]:48-50.


135. Thomas DB. Oral contraceptives and breast cancer: review of the epidemiologic literature. Contraception 1991;43:597-642.


136. Romieu I, Berlin JA, Colditz GA. Oral contraceptives and breast cancer: review and meta-analysis. Cancer 1990;66:2253-2263.


137. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev 1993;15:80-97.


138. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989;59:613-617.


139. Kay CR, Hannaford PC. Breast cancer and the pill - a further report from the Royal College of General Practitioners' oral contraception study. Br J Cancer 1988;58:675-680.


140. Romieu I, Willett WC, Colditz GA, et al. A prospective study of oral contraceptive use and the risk of breast cancer in women. J Natl Cancer Inst 1989;81:1313-21.


141. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control 1997;8:65-72.


142. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Biology of disease: comparison study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-278.


143. Wingo PA, Lee NC, Orv HW, Beral V, Peterson HB, Rhodes P. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstet Gynecol 1991;78:161-170.


144. White E, Malone KE, Weiss NS. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-514.


145. Collaborative Group on Hormonal Factors in Beast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996;54[Suppl]:1S-106S.


146. Stanford JL, Thomas DB. Exogenous progestin and breast cancer. Epidemiol Rev 1993;15:98-107.


147. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 1991;338:833-838.


148. Kennedy DL, Baum C. Noncontraceptive estrogen and progestins: use patterns over time. Obstet Gynecol 1985;65:441-446.


149. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.


150. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990.


151. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavnillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a metaanalysis. Obstet Gynecol 1992;79:286-294.